Rheumatoid arthritis (RA) remains a chronic and often treatment-resistant condition for many patients. While current therapies suppress immune responses, nearly one-third of patients still experience inadequate results over time. A team at RheumaGen, led by immunologist Brian Freed, is pursuing a different path—using gene editing to alter immune cell behavior at its source.
Their approach centers on human leukocyte antigen (HLA) proteins, specifically a variant known as *0401, which tends to misidentify collagen as a threat and trigger joint inflammation. Freed’s team discovered that swapping just one amino acid (lysine to glutamic acid) within this variant, through a CRISPR-based edit called K71E, effectively silenced the autoimmune response in preclinical models.
Notably, the team found that this minor change didn’t cause immune rejection in mice—even when transplanted—suggesting the immune system tolerated the edit without recognizing it as foreign. This allowed them to design a targeted bone marrow-based therapy that could replace faulty immune cells with corrected ones, potentially eliminating the need for systemic immunosuppressants.
Unlike conventional bone marrow transplants, which require aggressive preconditioning, RheumaGen’s proposed procedure would selectively edit a subset of the patient’s own cells. The goal is to restore tolerance without full immune ablation. However, questions remain about the level of replacement needed, long-term safety, and patient acceptability of the therapy, which still involves an invasive step.
Looking ahead, RheumaGen is preparing for a potential clinical trial by 2026. The therapy may eventually have broader implications, with the team exploring similar HLA-targeted strategies for type 1 diabetes and multiple sclerosis.
This research signals a shift toward more personalized, recognition-focused treatments for autoimmune disorders. While the road to human trials is cautious and complex, the concept of “retraining” the immune system at the molecular level marks a significant development in regenerative medicine.